Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma (Q38176547)

30 August 2017

title

Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma (English)

1 reference

30 August 2017

Mitsutoshi Nakada

1

1 reference

30 August 2017

Daisuke Kita

2

1 reference

30 August 2017

Takuya Watanabe

3

1 reference

30 August 2017

Yutaka Hayashi

4

1 reference

30 August 2017

Jun-ichiro Hamada

5

1 reference

30 August 2017

publication date

8 January 2014

1 reference

30 August 2017

published in

Brain Tumor Pathology

1 reference

30 August 2017

volume

31

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

198-207

1 reference

Targeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicine

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Aberrant signaling pathways in glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Epidermal growth factor receptor: a re-emerging target in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Individualized targeted therapy for glioblastoma: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

EGFR mutations and sensitivity to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2 and ABCG2- cancer cells are similarly tumorigenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Interaction of Tyrosine Kinase Inhibitors with the MDR-Related ABC Transporter Proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Molecular targets of glioma invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Receptor tyrosine kinases: principles and functions in glioma invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

'Go or grow': the key to the emergence of invasion in tumour progression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

EGFR gene amplification--rearrangement in human glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

The role of ABC transporters in drug resistance, metabolism and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10014-013-0174-9

10.1007/S10014-013-0174-9

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference